Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics Inc.

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Amicus, with a price target of $21.00. Kluska cove...

Market Cap	$2.84B	P/E Ratio	95.60
52W High	$10.36	52W Low	$5.51
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	41.9%	52W Position	83.5%
Overall Score	43	Value Score	20
Quality Score	--	Technical Score	66

EPS Current Est	$0.1	EPS Next Est	$0.43
EPS Growth Est	+330.0%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FOLD	$9.56	+1.16%	4.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FOLD	$9.56	+1.2%	4.02M
3
4
5
6

FOLD

FOLD

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Amicus Therapeutics Inc. Data in Excel

Get Amicus Therapeutics Inc. Data in Excel